Treatment found to improve cognitive improvement in patients with Fragile X syndrome

Results from phase two study show improved language and daily functioning among participants

An experimental treatment produced improvements in cognitive function and language in patients with fragile X syndrome, a study at Rush University Medical Center has found. fragile X syndrome (known as FXS for short) is the most common known genetic cause of autism and the most common cause of inherited intellectual disability.

“These results offer hope for patients with fragile X syndrome and their families” said Elizabeth Berry-Kravis, MD, PhD, a pediatric neurologist at Rush University Medical Center and principal investigator of the study. “The majority of clinical outcome measures were in favor of the drug. These measures included performance-based assessments and parent and physician-rated scales, which in combination, suggest a meaningful impact on the global FXS disease process.”

The study was a phase two clinical trial to assess the safety and efficacy of a drug known as BPN14770 in 30 men with between the ages of 18 and 41 years who have fragile X syndrome. BPN1477 inhibits the production of a family of enzymes known as phosphodiesterase‐4Dv (PDE4D), which control the availability in the brain of a cyclic adenosine monophosphate (cAMP), a molecule that is critically involved in memory formation.

By inhibiting PDE4D, the drug increases the levels of cAMP in the brain. “It’s exciting that we have a drug that potentially addresses a core deficit in FXS, a decrease in cAMP, that has been documented in patients, which I discovered during my pediatric neurology fellowship 30 years ago,” Berry-Kravis said.

Participants in the study received daily oral doses of BPN14770 twice a day or a placebo for 12 weeks. Parents, caregivers and physician raters were kept unaware of whether the participants received the treatment or the placebo.

The study evaluated the participants using a version of the National Institutes of Health Toolbox Cognitive Battery (a cognitive measure) that was modified to be effective in assessing people with intellectual disabilities. In addition, the study included scales on which parents’ rated of improvements from the drug.

“This is the first time that the NIH toolbox has been able to be used to demonstrate a cognitive change in a trial in people with intellectual disabilities,” Berry-Kravis said. “In just three months, we saw improvement specifically in the verbal subtests of the NIH toolbox, coupled with parent rating of improvements, particularly in language.”

Cognitive assessments using the NIH toolbox revealed significant benefit in oral reading recognition, picture vocabulary and the cognition crystallized composite score. Parent/caregiver ratings revealed benefit that was judged to be clinically significant in language and daily functioning.

After 12 weeks of treatment in the study, patients crossed over and took placebo if they had been taking drug, and drug if they had been taking placebo for another 12 weeks. The benefit of BPN14770 was found to persist up to 12 weeks after the crossover from drug to placebo. BPN14770 was very well tolerated, with few adverse events.

In laboratory studies, BPN14770 promoted the maturation of connections between neurons, which is impaired in patients with Fragile X Syndrome). This mechanism of action also may have potential to improve cognitive and memory function in Alzheimer’s disease and other dementias, learning/developmental disabilities and schizophrenia. At this time, however, the U.S. Food and Drug Administration only has approved BPN14770 for investigational use.